Smithers Viscient announces the appointment of Ian Siragher to the position of Managing Director
24.1.2019 13:30:00 EET | Business Wire | Press release
Smithers Viscient, a global contract research organization (CRO), today announced the appointment of Ian Siragher to the position of Managing Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190124005031/en/
Ian Siragher, Managing Director, Smithers Viscient Europe (Photo: Business Wire)
Siragher will assume operational responsibility for the Smithers Viscient European site in Harrogate, UK. His experience includes high technology start-ups, running SME business, sales, marketing and regulated industry programs within the analytical, pharmaceutical and drug delivery industries. He brings a wealth of entrepreneurial experience with proven strengths in scientific knowledge, operational and strategic planning, coupled with a strong client focus.
“We are delighted to welcome Ian to our business,” said Susan Shepherd, President, Smithers Viscient. “Ian is an excellent appointment for us; he is a proven operational leader having spent much of his career running a range of businesses.” Shepherd continues, “He brings an exceptionally strong global positioning and planning background, which is vital as we continue to grow our portfolio. His proven experience, vision and his ability to think strategically makes him an excellent choice in support of our clients around the globe.”
Siragher joins Smithers after 12 years as Managing Director and founder with Concept Life Sciences, formerly Agenda 1 Analytical Services Ltd. He holds an MBA, a Bsc (Hons) in Psychology and is an Associate of Chartered Institute of Bankers (ACIB). He has relocated to Harrogate to take up the position.
# # #
About Smithers Viscient
Smithers Viscient is a global contract research organization (CRO). The company delivers a comprehensive range of ecotoxicology, environmental fate, metabolism and chemistry services, for the pharmaceutical, crop protection, chemical, and consumer household product industries. Pollinator testing capabilities include laboratory-based studies, semi-field, and field exposures. With laboratories located in North America and Europe, Smithers Viscient, has performed standard guideline and higher-tiered environmental studies for 45 years. For more information about Smithers Viscient’s environmental regulatory testing solutions, visit http://smithersviscient.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190124005031/en/
Contact information
Smithers Viscient
Fiona Brook-Rogers
Marketing Manager
Europe
+44 (0) 1423 532 710
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Unveils Global Development Centre in Malaysia, Expanding Commitment to AI, Talent, Trust and Digital Innovation1.7.2026 12:06:00 EEST | Press release
Ant International today officially opened its Global Development Centre (GDC) in Kuala Lumpur, deepening its long-term commitment to Malaysia and Southeast Asia, and strengthening the country's role as a strategic hub for global innovation, digital talent, and next-generation financial technology. The unveiling ceremony was officiated by the Prime Minister of Malaysia, YAB Dato' Seri Anwar Ibrahim. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260701982923/en/ L to R: Datuk Fabian Bigar, Secretary General to Ministry of Digital, YB Senator Dato' Seri DiRaja Dr. Zambry bin Abd Kadir, Minister of Higher Education, YAB Dato' Seri Anwar Bin Ibrahim, Prime Minister of Malaysia, Cyril Han, CEO of Ant Group, Peng Yang, CEO of Ant International Ant International’s GDC is located at The Exchange 106, within TRX, Malaysia’s dedicated international financial centre. Cyril Han, CEO of Ant Group said, "With a visionary leadership and a
Haleon to Accelerate AI-powered Transformation With New Five-year Microsoft Collaboration1.7.2026 12:00:00 EEST | Press release
Haleon, a consumer health company solely focused on better everyday health, today announces a new five-year collaboration with Microsoft to scale digital, data and AI capabilities across the business and accelerate delivery of its global Win as One strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630342896/en/ The new agreement builds on Haleon’s existing use of Microsoft 365 Copilot and further supports the wider adoption of AI-powered tools across the business, helping teams automate routine tasks, collaborate more effectively and focus on higher-value work. Importantly, it will also further strengthen Haleon’s digital and AI-enabled infrastructure through further adoption of Microsoft’s agentic AI, security and identity capabilities, helping the company to scale AI securely and responsibly. Haleon and Microsoft will co-create high-impact AI use cases which deliver value across multiple critical functions, from
Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob
EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release
EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom